New ACC/AHA Dyslipidemia Guidelines Released

In this week's View, Dr. Eagle looks at data from the STS/ACC TVT Registry on off-label transcatheter valve interventions that demonstrate reduced residual tricuspid regurgitation (TR) and improved quality of life. He then explores the REVNOVATE-COMPLEX-PCI study that investigates the benefits of intravascular imaging guidance for five years. Finally, Dr. Eagle summarizes the ACC/AHA's newly released clinical guidelines for managing dyslipidemia.     Subscribe to Eagle's Eye View    

In this week's View, Dr. Eagle looks at the differential effect of bisoprolol versus verapamil in nonobstructive hypertrophic cardiomyopathy (HCM) treatment. He then explores lower heart failure (HF) hospitalization risk in patients with type 2 diabetes, comparing GLP-1RAs to DPP-4 inhibitors and similar outcomes with SGLT-2 inhibitors. Dr. Eagle then examines the use of shared decision-making and decision aids in percutaneous left atrial appendage occlusion (LAAO).  Finally, the iModern trial, which compares immediate percutaneous coronary intervention (PCI) guided by instantaneous wave-free ratio (iFR) and deferred PCI guided by cardiac stress magnetic resonance imaging (MRI) in patients with STEMI and multivessel disease, is discussed.   Subscribe to Eagle's Eye View    

In this week's View, Dr. Eagle looks at increased one-year mortality in younger patients undergoing transcatheter aortic valve replacement (TAVR). He then explores the PREDIMED trial which found that adherence to the Mediterranean diet plus moderate wine intake was associated with reduced cardiovascular risk and mortality. Finally, Dr. Eagle examines 20-year outcomes for pulmonary vein isolation (PVI) in patients with drug-refractory paroxysmal atrial fibrillation (AFib).   Subscribe to Eagle's Eye View    

In this week's View, Dr. Eagle looks at findings from the Evolut Low Risk trial in which self-expanding transcatheter aortic valve replacement (TAVR) versus surgery at six years in low-risk patients with aortic stenosis (AS) is considered. He then explores the TUXEDO-2 Trial evaluating ticagrelor versus prasugrel in percutaneous coronary intervention patients with diabetes and multivessel coronary disease (MVD). Finally, Dr. Eagle examines the first-ever release of the AHA/ACC guideline for treatment and management of acute pulmonary embolism (PE) in adults.    Subscribe to Eagle's Eye View   

In this week's View, Dr. Eagle looks at the ORBITA-2 trial and how percutaneous coronary intervention (PCI) may lead to greater symptom relief in older adults. He then explores the EQUAL trial that investigated how Apple smartwatch monitoring improves atrial fibrillation (AFib) detection. Finally, Dr. Eagle examines revelations from the EMPEROR-Preserved trial regarding interaction between SGLT2 inhibitors and baseline magnesium levels in treating patients who have either heart failure (HF) or HF with preserved ejection fraction (HFpEF).   Subscribe to Eagle's Eye View   

In this week's View, Dr. Eagle looks at exercise systolic blood pressure (SBP) during stress testing related to cardiovascular (CV) events. He then explores the novel Navitor transcatheter heart valve (THV) and its safety and effectiveness in younger patients requiring transcatheter aortic valve replacement (TAVR). Finally, Dr. Eagle examines the value of 18F-FAPI PET/CT imaging and its role in assessing risk in patients with pulmonary arterial hypertension (PAH).   Subscribe to Eagle's Eye View   

In this week's View, Dr. Eagle comments on the recently published JACC Cardiovascular (CV) Statistics report which evaluates the management of CV risk factors in the United States. He then explores the use of semaglutide and its association with reduced hospital admissions and length of stay. Finally, Dr. Eagle examines the multicenter, multinational ADJUST-DVT study on the age-adjusted use of D-dimer cut-offs for patients with suspected deep vein thrombosis.      Subscribe to Eagle's Eye View   

In this week's View, Dr. Eagle evaluates the impacts that reducing saturated fat have on mortality, nonfatal myocardial infarction (NFMI), and stroke in high-risk individuals. He then explores the SURPASS-CVOT study which considers if tirzepatide is superior to dulaglutide in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD). Next, he summarizes the FINEARTS-HF study and its investigation of finerenone and hypotension and CV outcomes according to baseline kidney function.  Finally, Dr. Eagle examines how low operator volume is associated with worse transcatheter aortic valve replacement (TAVR) and mitral transcatheter edge-to-edge repair (MTEER) outcomes.      Subscribe to Eagle's Eye View   

In this episode, Dr. Eagle looks back at 2025 and explores some of the significant developments that show how the College is responding to changes in the way we evaluate, manage, and follow patients with various types of cardiovascular disorders. His survey of topics that received the most attention include the new guidelines on hypertension, acute coronary syndromes, the management of adults with congenital heart disease, cardiogenic shock, pericarditis, sports cardiology, weight management, amyloid heart disease and inflammation. Last year's most popular articles include insights into SGLT-2 inhibitors in patients with heart failure with reduced ejection fraction (HFrEF), flu vaccines, anticoagulation, and much more impacting the changing landscape of cardiology.       Subscribe to Eagle's Eye View   

In this week's View, Dr. Eagle looks at the DANISH trial extended follow-up, evaluating which patients benefit most from primary prevention implantable cardioverter defibrillator (ICD) implantation. He then explores the SURMOUNT-4 study on weight reversal post tirzepatide withdrawal. Finally, Dr. Eagle examines two JACC articles that cover disease monitoring: one tracking the progression of transthyretin amyloid cardiomyopathy (ATTR-CM) and another assessing cardiovascular risks in patients receiving cancer therapy.     Subscribe to Eagle's Eye View